Litcius/Paper detail

Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/RAD)

Gabriella Macchia, Barbara Alicja Jereczek‐Fossa, Roberta Lazzari, A. Cerrotta, Francesco Deodato, Edy Ippolito, Cynthia Aristei, Maria Antonietta Gambacorta, Giovanni Scambia, Vincenzo Valentini, Gabriella Ferrandina

2021International Journal of Gynecological Cancer21 citationsDOI

Topics & Concepts

MedicineRadiation therapyClinical endpointRadiosurgeryClinical trialMagnetic resonance imagingProspective cohort studyPhases of clinical researchStage (stratigraphy)RadiologyDose fractionationOvarian cancerCancerSurgeryInternal medicinePaleontologyBiologyOvarian cancer diagnosis and treatmentPARP inhibition in cancer therapyBreast Cancer Treatment Studies
Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/RAD) | Litcius